Seamless gene correction of beta-thalassemia mutations in patient-specific cells

5 agosto 2014

A major hurdle in gene therapy is the efficient integration of a corrected gene into a patient’s genome without mutating off-target sites. In a new paper, scientists explain having used CRISPR/Cas genome editing technology to seamlessly and efficiently correct disease-causing mutations in cells from patients with beta-thalassemia.